ONM-501

ONM-501 is a dual-activating STING (Stimulator of Interferon Genes) agonist designed for intratumoral administration in oncology. It consists of a proprietary pH-sensitive polymer (PC7A, incorporating polyethylene glycol and poly(methyl methacrylate)) that forms micelles encapsulating the endogenous STING agonist 2',3'-cGAMP. This formulation enables both rapid and sustained activation of the STING pathway, leading to prolonged innate immune activation within tumors[1][6]. Preclinical studies have demonstrated that ONM-501 increases tumor-infiltrating T-cells, upregulates PD-L1 expression, and induces anti-tumor efficacy as monotherapy or in combination with anti-PD1 agents across multiple tumor models[1][8]. The drug is currently being evaluated in Phase 1 clinical trials for advanced solid tumors and lymphomas, both as monotherapy and in combination with cemiplimab (an anti-PD1 antibody)[2][5]. Developed by OncoNano Medicine, ONM-501 aims to enhance local immune responses against cancer while minimizing systemic toxicity through its unique nanoparticle delivery system[7].

Other names

环状单磷酸鸟苷-单磷酸腺苷-ONM-501